Reglan Tardive Dyskinesia: Adverse Event Reports (NY)

Latest update (2025-07)

FDA enforcement record (Ongoing): Presence of foreign tablets/capsules. [source]

From General Health Awareness to Occupational Exposure

If you or a loved one has developed uncontrollable facial or body movements after taking Reglan, you may be experiencing tardive dyskinesia. This condition is a known side effect of metoclopramide, especially with long-term use. Building on decades of medical research into drug-induced movement disorders, this page explains the diagnosis, symptoms, and regulatory context of Reglan-associated tardive dyskinesia.

Understanding Reglan and Its Approved Uses

Reglan, the brand name for metoclopramide, is a medication approved for short-term use in adults with specific gastrointestinal conditions. Its approved indications include treatment for 4 to 12 weeks of symptomatic, documented gastroesophageal reflux in adults who fail to respond to conventional therapy, and relief of symptoms in adults with acute and recurrent diabetic gastroparesis (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). However, Reglan carries a significant risk of causing tardive dyskinesia (TD), a potentially irreversible serious movement disorder. The risk of developing TD increases with duration of treatment and total cumulative dosage (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). Reglan is contraindicated in patients with a history of TD, and the medication should be used for the shortest duration necessary, with periodic reassessment of the need for continued treatment (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397).

Tardive Dyskinesia: Symptoms, Diagnosis, and Mechanism

Tardive dyskinesia is characterized by involuntary, repetitive movements, often involving the face, tongue, or extremities. These movements can be disfiguring and may persist even after the medication is discontinued. The clinical presentation of TD can vary, but common signs include grimacing, tongue protrusion, lip smacking, and rapid eye blinking. Diagnosis is based on clinical evaluation and a history of exposure to a dopamine-blocking agent like metoclopramide. The mechanistic pathway linking Reglan to TD involves the drug's action as a dopamine receptor antagonist in the brain, which can lead to dopamine receptor supersensitivity over time, contributing to the development of abnormal involuntary movements. The FDA-approved labeling for Reglan includes a boxed warning that explicitly states the risk of TD. The warning emphasizes that metoclopramide, including Reglan, can cause TD, and that the risk increases with longer treatment duration and higher cumulative doses (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397).

Duration of Use and Monitoring Recommendations

For patients with symptomatic, documented gastroesophageal reflux, the maximum duration of Reglan treatment is 12 weeks (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). In patients with diabetic gastroparesis, total treatment duration should also be avoided for longer than 12 weeks; if longer-term use is unavoidable, routine monitoring for signs and symptoms of TD is recommended (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). Reglan tablets are not recommended for use in pediatric patients due to the risk of developing TD and other extrapyramidal symptoms (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). Despite these warnings, there have been concerns about the adequacy of warnings provided to patients and healthcare providers regarding the risk of TD from Reglan. Some patients may have been prescribed Reglan for extended periods beyond the recommended 12-week limit, or without adequate monitoring for early signs of TD. The latency period between exposure to Reglan and the onset of TD can vary, with some patients developing symptoms after months or years of use. The timeline between exposure and documented harm is critical for understanding the potential for legal action.

Statute of Limitations for Reglan Claims in New York

For affected patients in New York, attorney-related considerations are important. The statute of limitations for filing a personal injury lawsuit related to Reglan-induced TD in New York is generally three years from the date of injury or from when the injury was discovered, or reasonably should have been discovered. This means that patients who have developed TD after taking Reglan may have a limited window to pursue legal action. It is essential for affected individuals to consult with an attorney experienced in pharmaceutical litigation to understand their rights and the specific deadlines that apply to their case. In summary, Reglan is associated with a well-documented risk of causing tardive dyskinesia, a potentially irreversible movement disorder. The FDA-approved labeling includes a boxed warning about this risk, but concerns about the adequacy of warnings persist. Patients who have developed TD after taking Reglan should be aware of the statute of limitations in New York and seek legal advice promptly to preserve their ability to pursue compensation for their injuries.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the statute of limitations for Reglan-induced tardive dyskinesia in New York?

In New York, the statute of limitations for filing a personal injury lawsuit related to Reglan-induced tardive dyskinesia is generally three years from the date of injury or from when the injury was discovered, or reasonably should have been discovered. It is crucial to consult with an attorney promptly to ensure your claim is filed within the applicable deadline.

What are the symptoms of tardive dyskinesia caused by Reglan?

Tardive dyskinesia is characterized by involuntary, repetitive movements, often involving the face, tongue, or extremities. Common signs include grimacing, tongue protrusion, lip smacking, and rapid eye blinking. These movements can be disfiguring and may persist even after the medication is discontinued.

How long can Reglan be used safely?

Reglan is approved for short-term use, typically up to 12 weeks for gastroesophageal reflux and diabetic gastroparesis. The risk of developing tardive dyskinesia increases with longer treatment duration and higher cumulative doses. Use beyond 12 weeks is not recommended without careful monitoring.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Reglan exposure and a confirmed Tardive Dyskinesia diagnosis may request an independent eligibility review. [Begin Assessment]

References

DailyMed - Reglan Labeling

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.